[go: up one dir, main page]

JOP20200257A1 - تركيبات أوليجو نوكليوتيد وطرق لتحضيرها - Google Patents

تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Info

Publication number
JOP20200257A1
JOP20200257A1 JOP/2020/0257A JOP20200257A JOP20200257A1 JO P20200257 A1 JOP20200257 A1 JO P20200257A1 JO P20200257 A JOP20200257 A JO P20200257A JO P20200257 A1 JOP20200257 A1 JO P20200257A1
Authority
JO
Jordan
Prior art keywords
free
amino group
oligonucleotide
nucleoside
methods
Prior art date
Application number
JOP/2020/0257A
Other languages
English (en)
Inventor
H Ramiya Premchandran
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of JOP20200257A1 publication Critical patent/JOP20200257A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع بتوفير طريقة ذات طور صلب لعمل أوليجو نوكليوتيدات من خلال دورات الإقران المتعاقب بما في ذلك خطوة إقران واحدة على الأقل لوحدة فرعية من داي نوكليوتيد دايمر بمجموعة طرفية 3’ حرة لسلسلة متنامية. تتضمن أوليجو نوكليوتيد وحدتين فرعيتين على الأقل من النوكليوزيد مرتبطة بواسطة رابط فوفسوراميدات N3? ?P5?. يمكن أن تتضمن الطريقة الخطوات (أ) نزع حماية مجموعة أمينية 3' تمت حمايتها للنوكليوزيد الطرفي المرتبط بمادة حاملة في الطور الصلب، تُشكل خطوة نزع مجموعة الحماية المذكورة مجموعة أمينية 3' حرة؛ (ب) تلامس المجموعة الأمينية 3' الحرة مع أمينو -داي نوكليوتيد- 5 - فوسفوراميديت دايمر تمت حمايته عند الطرف 3? في وجود محفز نوكليوتيد لتشكيل رابط نوكليوزيد N3? ?P5? فوسفوراميديت؛ و (ج) أكسدة الرابط (أي، المعالجة بالسلفر). يمكن أن تتضمن التركيبات المنتجة بواسطة الطرق المذكورة كمية قليلة من واحدة او أكثر (N-x) من منتجات أوليجو نوكليوتيد. يتم أيضاً توفير تركيبات صيدلية تتضمن تركيبات أوليجو نوكليوتيد التي يتعلق بها الاختراع.
JOP/2020/0257A 2014-05-01 2014-05-01 تركيبات أوليجو نوكليوتيد وطرق لتحضيرها JOP20200257A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US201562151909P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
JOP20200257A1 true JOP20200257A1 (ar) 2017-06-16

Family

ID=54359301

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0257A JOP20200257A1 (ar) 2014-05-01 2014-05-01 تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
JOP/2015/0089A JO3767B1 (ar) 2014-05-01 2015-04-29 تراكيب اوليغو نوكليوتيد و طرق تصنيعها

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2015/0089A JO3767B1 (ar) 2014-05-01 2015-04-29 تراكيب اوليغو نوكليوتيد و طرق تصنيعها

Country Status (34)

Country Link
US (6) US9796747B2 (ar)
EP (2) EP4286519A3 (ar)
JP (6) JP7040892B2 (ar)
KR (4) KR20240144488A (ar)
CN (3) CN111228288B (ar)
AP (1) AP2016009489A0 (ar)
AU (3) AU2015253158B2 (ar)
BR (1) BR112016025196B1 (ar)
CA (1) CA2943888A1 (ar)
CL (4) CL2016002749A1 (ar)
DK (1) DK3137479T5 (ar)
EA (1) EA034882B9 (ar)
ES (1) ES2963740T3 (ar)
FI (1) FI3137479T3 (ar)
HR (1) HRP20231505T1 (ar)
HU (1) HUE064289T2 (ar)
IL (2) IL248044B (ar)
JO (2) JOP20200257A1 (ar)
LT (1) LT3137479T (ar)
MA (1) MA63525B1 (ar)
MX (2) MX382233B (ar)
MY (2) MY196927A (ar)
PE (1) PE20170147A1 (ar)
PH (1) PH12016502080A1 (ar)
PL (1) PL3137479T3 (ar)
PT (1) PT3137479T (ar)
RS (1) RS64860B1 (ar)
SG (2) SG11201608226YA (ar)
SI (1) SI3137479T1 (ar)
SM (1) SMT202300405T1 (ar)
TW (2) TWI709406B (ar)
UA (1) UA126108C2 (ar)
WO (1) WO2015168310A1 (ar)
ZA (2) ZA201606624B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1778711T3 (en) 2004-07-02 2017-10-02 Geron Corp SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
AU2016250576C1 (en) * 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
HUE056722T2 (hu) * 2017-07-10 2022-03-28 Geron Corp Javított eljárás imetelstat elõállítására
IL292327A (en) 2019-10-28 2022-06-01 Geron Corp Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same
AU2020372865A1 (en) 2019-10-28 2022-05-26 Geron Corporation Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1-(protected hydroxy)-propane salts and methods of making the same
US20240391945A1 (en) * 2020-01-08 2024-11-28 Nitto Denko Corporation Nucleic acid synthesis method using segment-type amidite

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DK0462145T3 (da) 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
JPH05505941A (ja) 1990-03-29 1993-09-02 ギリード　サイエンシズ　インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
CA2174425A1 (en) 1993-10-18 1995-04-27 Graham Leslie Barrett A method for enhancing neurone survival and agents useful for same
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
CZ274596A3 (en) 1994-03-18 1997-03-12 Lynx Therapeutics Oligonucleotide n3 - p5 phosphoramidates and process of their synthesis and hybridization
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
CZ3497A3 (en) 1994-07-07 1997-10-15 Geron Corp Rna component of mammal telomerase, oligonucleotide, recombinant expression plasmid containing the oligonucleotide, process for preparing eukaryotic host cell, process for preparing a recombinant telomerase enzyme
AU4101396A (en) 1994-11-07 1996-05-31 Hybridon, Inc. Synthesis of 35s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) * 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
JP2001507229A (ja) 1996-12-20 2001-06-05 ジェロン コーポレイション テロメラーゼのｒｎａ成分を検出および阻害するための方法
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4267233B2 (ja) * 1999-09-10 2009-05-27 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4854913B2 (ja) * 2001-03-23 2012-01-18 ジェロン・コーポレーション オリゴヌクレオチド結合体
SI1667522T1 (en) 2003-09-09 2018-04-30 Geron Corporation Modified oligonucleotides for the inhibition of telomerase
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
DK1778711T3 (en) 2004-07-02 2017-10-02 Geron Corp SYNTHESIS OF PROTECTED 3'-AMINONUCLEOSIDE MONOMERS
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US20070269870A1 (en) * 2004-10-18 2007-11-22 George Church Methods for assembly of high fidelity synthetic polynucleotides
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8153604B2 (en) * 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
ES2986404T3 (es) 2006-10-30 2024-11-11 Geron Corp Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Also Published As

Publication number Publication date
LT3137479T (lt) 2023-10-10
AP2016009489A0 (en) 2016-10-31
PE20170147A1 (es) 2017-04-12
US20180016294A1 (en) 2018-01-18
MX2016014178A (es) 2017-05-04
SG11201608226YA (en) 2016-10-28
EP4286519A2 (en) 2023-12-06
IL248044A0 (en) 2016-11-30
EP3137479A4 (en) 2018-02-07
CN117357548A (zh) 2024-01-09
ZA201606624B (en) 2020-12-23
EP4286519A3 (en) 2024-02-28
AU2022203273A1 (en) 2022-06-02
EP3137479B1 (en) 2023-08-30
MX2021004932A (es) 2021-08-16
US20180016293A1 (en) 2018-01-18
JO3767B1 (ar) 2021-01-31
JP2022044679A (ja) 2022-03-17
CN111228288A (zh) 2020-06-05
ES2963740T3 (es) 2024-04-01
NZ763996A (en) 2021-03-26
CN111228288B (zh) 2023-10-20
KR102316282B1 (ko) 2021-10-25
JP7040892B2 (ja) 2022-03-23
CL2018001212A1 (es) 2018-08-03
JP2018131453A (ja) 2018-08-23
MA63525A1 (fr) 2024-09-30
IL268570A (en) 2019-09-26
KR20230088509A (ko) 2023-06-19
PT3137479T (pt) 2023-11-30
JP2023073510A (ja) 2023-05-25
RS64860B1 (sr) 2023-12-29
MY178617A (en) 2020-10-19
FI3137479T3 (fi) 2023-11-28
JP2020050670A (ja) 2020-04-02
US11739114B2 (en) 2023-08-29
TW202017574A (zh) 2020-05-16
DK3137479T3 (da) 2023-11-20
MY196927A (en) 2023-05-11
SI3137479T1 (sl) 2023-11-30
ZA202005857B (en) 2024-01-31
UA126108C2 (uk) 2022-08-17
EP3137479A1 (en) 2017-03-08
CN106459134A (zh) 2017-02-22
US20150337314A1 (en) 2015-11-26
PH12016502080A1 (en) 2017-01-09
BR112016025196B1 (pt) 2022-08-02
JP2017514479A (ja) 2017-06-08
CA2943888A1 (en) 2015-11-05
JP2021182946A (ja) 2021-12-02
US20220306676A1 (en) 2022-09-29
AU2020201707A1 (en) 2020-03-26
US9796747B2 (en) 2017-10-24
US20250011359A1 (en) 2025-01-09
TW201622732A (zh) 2016-07-01
DK3137479T5 (da) 2024-10-14
HRP20231505T1 (hr) 2024-03-01
SMT202300405T1 (it) 2024-01-10
KR20240144488A (ko) 2024-10-02
NZ724764A (en) 2021-02-26
WO2015168310A1 (en) 2015-11-05
US11299511B2 (en) 2022-04-12
KR20160147768A (ko) 2016-12-23
IL248044B (en) 2019-08-29
MX382233B (es) 2025-03-13
TWI712413B (zh) 2020-12-11
AU2015253158B2 (en) 2019-12-12
EA034882B9 (ru) 2020-07-13
KR20210130822A (ko) 2021-11-01
AU2020201707B2 (en) 2022-02-17
PL3137479T3 (pl) 2024-02-26
KR102707216B1 (ko) 2024-09-19
BR112016025196A2 (pt) 2017-12-12
SG10201911086XA (en) 2020-01-30
CN106459134B (zh) 2020-02-18
MA63525B1 (fr) 2025-02-28
CL2016002749A1 (es) 2017-04-28
EA201691786A1 (ru) 2017-04-28
US10392418B2 (en) 2019-08-27
HUE064289T2 (hu) 2024-02-28
JP7308309B2 (ja) 2023-07-13
IL268570B (en) 2021-10-31
TWI709406B (zh) 2020-11-11
US20240150391A1 (en) 2024-05-09
CL2022000202A1 (es) 2023-02-10
EA034882B1 (ru) 2020-04-01
CL2018001213A1 (es) 2018-08-03
AU2015253158A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
JOP20200257A1 (ar) تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
CY1124632T1 (el) Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες
MX2025000894A (es) Composiciones de oligonucleotidos y metodos de los mismos
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
MX2016005876A (es) Óptimos loci de maíz.
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
WO2015066636A3 (en) Optimal maize loci
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
CY1121110T1 (el) Αντινοηματικα-ολιγονουκλεοτιδια ως παρεμποδιστες σηματοδοτησης tgf-r
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
PE20141541A1 (es) Metodos y composiciones para producir arroz resistente a inhibidores de accasa
MX2022003952A (es) Conjugados de biomoleculas.
EA201890379A1 (ru) Терапевтические олигонуклеотиды
IN2015DN02699A (ar)
EA202090282A1 (ru) Композиции олигонуклеотидов и способы их получения
TH166778A (th) องค์ประกอบโอลิโกนิวคลีโอไทด์และวิธีการในการทำองค์ประกอบนี้
AR100235A1 (es) Composiciones de oligonucleótidos y métodos para realizarlas
MX2016014556A (es) Nucleasa efectora tal para la inactivacion especifica del correceptor del vih ccr5.
AR105066A1 (es) Enzimas y sistemas crispr
RU2013106976A (ru) Набор синтетических олигонуклеотидов для амплификации и секвенирования its1-5.8s-its2 сосудистых растений
TH182360A (ar)